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The cytochrome P450 (CYP) enzymes are responsible for the 
oxidation of a diverse range of xenobiotic and endogenous 
compounds. There are 57 transcriptionally active genes encoding 
CYPs, which are classified into families and subfamilies 
according to their nucleotide sequence.
1
 CYPs function mainly to 
detoxify xenobiotics and endogenous molecules, but some 
evidence also indicates a link to signaling events.
2
 Many probes 
based on various chemical scaffolds have been explored in order 
to identify chromophores that can be used to explore CYP 
activity.
3
 Generally, it has proven difficult to develop CYP 
isoform-selective fluorophores, in particular because CYPs are 
encoded by large gene families, and their functions cannot be 
predicted from their gene sequence.
4
 However, it is possible to 
achieve CYP-selectivity as we have shown with duocarmycin 
bioprecursors reengineered to target CYP1A1 and CYP2W1 for 
tumour-selective bioactivation.
5-7
 However, the duocarmycin 
scaffold
8
 is not suited as a fluorophore for monitoring CYP 
functional activity as the pharmacophore is poorly fluorescent. 
Nemorubicin (3’-deamino-3’-[2-(S)-methoxy-4-morpholi-
nyl]doxorubicin; MMDX, 1), a doxorubicin derivative bearing a 
methoxymorpholinyl group on the carbohydrate moiety, has 
undergone clinical evaluation.
9
  MMDX is at least 80-fold more 
potent in vivo compared with doxorubicin, which is attributed to 
generation of metabolite PNU-159682 (2) via CYP3A 
bioactivation that can covalently adduct DNA.
10, 11
  The latter is 
likely to follow DNA intercalation via the planar anthraquinone 
pharmacophore, which we have explored to discover libraries of 
dual-targeting DNA-affinic covalent binding agents.
12-18
 The 
anthraquinone also plays a key part in the anticancer drug 
mitoxantrone (3) and DRAQ5 (4), a far-red DNA label used to 
detect nuclei and quantify DNA content in live or fixed cells.
19, 20
 
The anthraquinone possesses fluorescent properties that can be 
exploited in measuring nuclear or cytoplasmic events.
21
 Here, we 
speculated whether combining features of MMDX and 
DRAQ5
TM
 could be used to discover new molecules, which could 
simultaneously be used to assess CYP functional activity across a 
heterogeneous cell population.  
 
 
 
 
 
 
 
 
 
 
    
Figure 1 Anthraquinone-based bioactive compounds 
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Structural features from the anticancer prodrug nemorubicin (MMDX) and the DNA-binding 
molecule DRAQ5
TM
 were used to prepare anthraquinone-based compounds, which were 
assessed for their potential to interrogate cytochrome P450 (CYP) functional activity and 
localisation. 1,4-disubstituted anthraquinone 8 was shown to be 5-fold more potent in EJ138 
bladder cancer cells after CYP1A2 bioactivation. In contrast, 1,5-bis((2-morpholinoethyl)amino) 
substituted anthraquinone 10 was not CYP-bioactivated but was shown to be fluorescent and 
subsequently photo-activated by a light  pulse (at a bandwidth 532 to 587 nm), resulting in 
punctuated foci accumulation in the cytoplasm. It also showed low toxicity in human 
osteosarcoma cells. These combined properties provide an interesting prospective approach for 
opto-tagging single or a sub-population of cells and seeking their location without the need for 
continuous monitoring.  
2009 Elsevier Ltd. All rights reserved. 
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Scheme 1 Synthesis of target compounds 7, 8 and 10. (i) H2NCH2CH2NH2 
(neat), 42%, (ii) 5, NaBH3CN, glacial acetic acid, 32%, (iii) amine (neat), 
78%, (iv) excess amine (neat), 50 ºC, 1-3 h, 60-85%  
Synthesis of target anthraquinone probes 7, 8 and 10 were 
prepared from either 1-monosubstituted building block 6 or 
commercially available 9. Compound 6 was reacted with neat 
ethylenediamine and purified by column chromatography before 
the resulting 1,4-disubsituted aminoanthraquinone was reacted 
with 2-methoxy-2-(2-oxoethoxy)acetaldehyde 5 under reductive 
amination conditions to produce target molecule 7.
22
 Intermediate 
5 was generated following the published procedure.
23
 
Anthraquinone probes 8
24
 and 10
25, 26
 were obtained by stirring 6 
or 9 respectively in neat 2-morpholinoethylamine followed by 
removal of excess amine and purification by flash column 
chromatography. 
To determine if compounds 7 and 8 were substrates for CYP 
bioactivation. We evaluated these in the EJ138 bladder cancer 
cell line (identical to the T24 cell line
27
) due to its very low levels 
of CYPs.
6
 Using previously published methodology,
28
 
metabolites were generated via incubation of compounds 7 and 8 
with 20 pmol CYP bactosomes in 50 mM Tris-HCl buffer (2 mM 
NADPH, 1 mM MgCl2, pH 7.4). Generally, none of the extracted 
metabolite incubates were shown to exert increased anti-
proliferative activity over their parental compounds 7 and 8 using 
the MTT assay (Table 1). The only exception was that CYP1A2-
mediated metabolites from incubation with compound 8 
possessed approximately a 5-fold potentiation in activity. 
Evaluation was also performed in SW480-mock and 2W1-
transfected colon carcinoma cell lines,
7
 but no bioactivation was 
observed for compounds 7 (IC50 = 1.27 µM in mock cells and 
1.53 µM in CYP2W1 cells) and 8 (IC50 = 0.97 µM in mock cells 
and 1.25 µM in CYP2W1 cells).  
Both the morpholinyl and 2-methoxymorpholinyl moieties 
contain motifs that could be hydroxylated by CYPs in the 3-
position with loss of H2O and generation of activated imine or 
hydroxylation at the 3-methoxy group with loss of formaldehyde,  
ring opening and generation of an aldehyde intermediate. Such 
CYP-bioactivated metabolites would have the propensity to form 
covalent adducts with DNA and hence increased potency would 
be expected. However, the lack of any significant bioactivation 
by CYP3A4 and 3A5 indicates that the carbohydrate moiety of 1 
in the proximity of the 2-methoxymorpholino group, subsequent 
to CYP3A hydroxylation, is vital for intramolecular formation of 
a potent cytotoxin and emphasizes the importance of the MMDX 
structural configuration.
10
  
To investigate the fluorescent properties of the compounds we 
decided to use human non-small cell lung (A549) and 
osteosarcoma (U2-OS) cancer cell lines, which we routinely use 
as models for assessing compounds with fluorescent properties
20, 
29
; these cell lines are also relevant for studying CYP1A2 as the 
human protein atlas shows moderate expression levels of its 
isoform in both cell types, with U-2 OS cancer cells showing 2-
fold RNA levels above A549 cancer cells.
30 
The absorbance spectrum of 7 alone (Fig. 2A) gave two 
maxima at wavelengths 610 and 650 nm; with an emission 
profile peak at 690nm and hence the compound can be best 
detected at a bandwidth of 650-790 nm. The molecule was 
readily taken up by living A549 cells and was shown to be 
localised in the peri-nuclear vesicular region of cells (Fig. 2D). 
The lack of DNA binding by compound 7 is evidenced by a 
nuclear-to-cytoplasmic (n/c) ratio of fluorescence intensity of 
0.3± 0.06 (n= 9). In contrast, the benchmark molecule DRAQ5™ 
gave a similar far-red spectral performance, but a n/c ratio of 7.7 
±1.8 (n=6). Unlike compounds 7 and 10 DRAQ5™ has two 
highly DNA affinic moieties in the 1,5 position of the 
anthraquinone chromophore, giving an equilibrium of nuclear 
compartment localisation and hence the molecule binds DNA in 
a stoichiometric fashion. Next we interrogated molecule 10 
without the 3-methoxy functionality to assess the effect of the 
unsubstituted morpholinyl moiety on fluorescent signal while 
maintaining the 1,5-disubstituted anthraquinone symmetry. This 
probe showed a blue-shifted absorbance profile to a single peak 
of 520nm with an emission profile maxima at 635nm (Fig. 2B). 
However, continuous exposure to 20µM of 10 again in A549 
cells resulted in a distinct nuclear labelling and a perinuclear 
compartment which also contained bright punctate labelling (Fig 
2E) and a n/c ratio of 4.1 ± 0.7 (n=17). The lower ratio compared 
to DRAQ5™ indicated that this molecule can be found in both 
these compartments. In addition the bright punctate labelling was 
acquired as a result of the pulsed light exposure (Fig 2E). 
Compounds 7 and 10 were then loaded into cells within a context 
of a timelapse screen to determine if the monitored cells were 
able to continue to undergo cell proliferation when exposed to 2 
or 20µM. U-2 OS cells exposed to the high dose of compound 10 
continued to proliferate after 48 hours (Fig. 3A) compared to 7 
where there was evidence of cell death at this dose (not shown).  
Recently, we reported on compound 10 and its ability to 
stabilise i-Motif forming DNA sequences and found it a poor 
ligand in contrast to mitoxantrone and other anthraquinones.
25
 
Interestingly, in this study, 10 was activated by light (at a 
bandwidth 532 to 587 nm), resulting in punctuated foci 
accumulation in the cytoplasm (not the nucleus), probably this is  
 
Table 1. Growth inhibition of parental anthraquinone and CYP bactosomes generated metabolite fractions against EJ138 cell line 
a IC50 (µM) values are the mean ± SD of at least three independent assays; PF = potentiation factor  
ID EJ138 CYP1A1 PF CYP1A2 PF CYP1B1 PF CYP2D6 PF CYP3A4 PF CYP3A5 PF 
7 0.32 ± 0.02 0.28 ± 0.06 1.1 0.25 ± 0.04 1.3 0.34 ± 0.04 0.9 0.31 ± 0.05 1.0 0.29 ± 0.09 1.1 0.25 ± 0.02 1.3 
8 0.34 ± 0.04 0.30 ± 0.08 1.1 0.07 ± 0.01 4.6 0.28 ± 0.09 1.2 0.25 ± 0.06 1.3 0.33 ± 0.06 1.0 0.36 ± 0.02 0.9 
due to the morpholino ring and independent of the 2-
methoxymorpholino functionality (Fig 3B). To our knowledge 
there is no report of such observation in the literature and thus 
warrants further investigation. 
Figure 2. Fluorescence profiles and cellular localisation of 7 and 10 
benchmarked against DRAQ5™. Absorbance spectrum (line) and 
associated fluorescent emission spectrum, as a result of excitation at 610nm 
(dots) for compound 7 (A) and 520nm for 10 (B) and DRAQ5™ (C). Single 
optical section of A549 cells obtained using confocal laser scanning 
microscopy. Images captured after 1h (20 µM) exposure of 7 (D) and 10 (E) 
and DRAQ5™ (F). Note also the nuclear to cytoplasmic ratio of mean 
fluorescence in each compartment is also given. Bar = 10µm 
Figure 3. Compound 10 shows low toxicity and photo-activation 
properties at 20µM in human osteosarcoma cells (U-2 OS) over 48 hours. 
(A) Short phase contrast timelapse sequence (each 20 mins apart) showed cell 
division was prevalent at time 0h and after a 48 hour exposure in live U-2 OS 
cells; *indicates the location of mitosis and the subsequent two daughter cells. 
(B) Fixed U-2 OS cells labelled with 10 for 1 hr, exposed to a 250ms pulse of 
excitation light (using a x20 0.8NA lens), excitation 560/40nm and emission 
detection at 630/75 nm. A second identical exposure caused the appearance of 
punctate foci located in the cytoplasm. This was not to the same extent across 
all cells. Bar = 10 µm 
The 2-methoxymorpholinyl moiety tethered to the anthraquinone 
did not result in CYP3A bioactivation as previously 
demonstrated for MMDX, however the simpler morpholinyl 
analogue 8 was 5-fold bioactivated by CYP1A2 bactosomes. 
Further medicinal chemistry optimisation of 8 could lead to a 
probe, which could be used to track CYP1A2 functional activity 
in human cells. Furthermore, the 1,5-disubstituted scaffold as in 
probe 10 is a useful starting point for more focused structure-
activity relationship studies aimed at determining selective 
probes with punctuated fluorescent emission/excitation signature 
together with limited background sample auto-fluorescence. 
These unique properties provide the capacity for specific cell 
opto-tagging (through a directed laser beam or aperture 
illumination), where these cells, with the acquired activated 
punctate features, can be identified at a subsequent time point 
without the need for continuous observation - hence a potential 
tool for monitoring selective cell fate.    
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